Galera Therapeutics Past Earnings Performance

Past criteria checks 0/6

Galera Therapeutics's earnings have been declining at an average annual rate of -7.6%, while the Biotechs industry saw earnings growing at 12.7% annually.

Key information

-7.6%

Earnings growth rate

81.5%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	n/a
Net Margin	n/a
Last Earnings Update	31 Dec 2023

Recent past performance updates

No updates

Recent updates

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Jun 29

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Jun 15

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Mar 23

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 24

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

Dec 24

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Nov 04

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Aug 05

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 17

Galera Therapeutics EPS beats by $0.08

Nov 10

Revenue & Expenses Breakdown
Beta

How Galera Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:GRTX Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	-59	23	24
30 Sep 23	-70	26	29
30 Jun 23	-71	26	31
31 Mar 23	-64	22	30
31 Dec 22	-62	20	31
30 Sep 22	-63	20	32
30 Jun 22	-69	21	39
31 Mar 22	-77	21	48
31 Dec 21	-81	21	52
30 Sep 21	-84	20	58
30 Jun 21	-78	18	55
31 Mar 21	-75	17	53
31 Dec 20	-74	16	55
30 Sep 20	-72	14	54
30 Jun 20	-70	12	52
31 Mar 20	-65	10	48
31 Dec 19	-59	8	42
30 Sep 19	-52	7	36
30 Jun 19	-43	7	29
31 Mar 19	-36	6	23
31 Dec 18	-30	6	19

Quality Earnings: GRTX is currently unprofitable.

Growing Profit Margin: GRTX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: GRTX is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.

Accelerating Growth: Unable to compare GRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).

Return on Equity

High ROE: GRTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Galera Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

New major risk - Financial position

Galera Therapeutics Receives Non-Compliance Letters from the Listing Qualifications Staff of Nasdaq

New major risk - Market cap size

New major risk - Revenue and earnings growth

Price target increased by 25% to US$0.50

Insufficient new directors

Galera Therapeutics Receives Notice from Nasdaq Regarding Listing Rule 5450(B)(2)(C)

Galera Therapeutics Receives Two Non-Compliance Notices from Nasdaq

New minor risk - Share price stability

Galera Therapeutics, Inc. Approves Reduction in the Company's Current Workforce by 22 Employees, or Approximately 70% of the Company's Headcount

Consensus revenue estimates increase by 17%

New minor risk - Market cap size

Galera Therapeutics, Inc. Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting

Insufficient new directors

Consensus revenue estimates increase by 100%

Price target decreased by 11% to US$10.00

CEO, President & Director recently bought US$168k worth of stock

Price target increased by 11% to US$12.50

Galera Therapeutics, Inc. Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis

Galera Therapeutics Receives Non-Compliance Notice from Nasdaq

Price target decreased to US$11.25

Price target increased to US$15.00

Price target increased to US$15.00

Galera Therapeutics, Inc. Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Therapeutics, Inc Appoints Eugene P. Kennedy as Chief Medical Officer

Galera Therapeutics appoints chief medical officer

Price target increased to US$15.00

Galera Therapeutics, Inc. Announces Results from Phase 1 Stage of Greco-1 Trial of Rucosopasem with SBRT for Nsclc

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Galera Therapeutics Receives Non-Compliance Letter from Nasdaq

Galera Therapeutics, Inc. Announces Oral Presentation At 2022 American Society of Clinical Oncology Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Galera Announces Plan to Submit Avasopasem NDA by Year End

Galera Therapeutics, Inc. Announces Topline Results from Phase 2A Aesop Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis

Galera to Present at 2022 American Society of Clinical Oncology Annual Meeting

Price target increased to US$12.25

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

Independent Director recently bought US$55k worth of stock

Galera Therapeutics, Inc. Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Price target decreased to US$11.50

Chief Medical Officer exercised options and sold US$288k worth of stock

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell 3000E Index

Independent Director recently bought US$91k worth of stock

Galera Therapeutics, Inc. Ceases Enrolling Subjects in its Phase 2 Pilot Trial of Avasopasem in Hospitalized Patients

Independent Director recently bought US$173k worth of stock

Consensus forecasts updated

Galera Therapeutics, Inc. Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer

Price target increased to US$20.75

CEO, President & Director exercised options to buy US$1.8m worth of stock.

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

New 90-day high: US$12.39

Chief Accounting Officer exercised options and sold US$179k worth of stock

Galera Therapeutics EPS beats by $0.08

New 90-day high: US$12.81

New 90-day high: US$9.81

New 90-day low - US$6.96

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell 3000 Value Index

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell Microcap Value Index

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta